About pegvaliase pqpz
Phenylalanine-metabolizing enzyme
Used for
- Lowers blood phenylalanine in adults with phenylketonuria (PKU) and uncontrolled levels despite existing management.
Usual adult dose
Starts at 2.5 mg subcutaneously once weekly for four weeks; gradually increases under specialist supervision. Maintenance is usually 20–60 mg daily.
Common side effects
- Injection-site reactions
- Joint pain
- Headache
- Anaphylaxis and other allergic reactions
Important warnings
- Anaphylaxis can occur, including after long-term treatment; emergency treatment may be needed.
- Patients must carry prescribed epinephrine and be trained to use it.
- Requires monitoring of blood phenylalanine and dose adjustments by a healthcare professional.
- May reduce blood phenylalanine excessively; dietary protein and phenylalanine intake may need adjustment.
Pregnancy
Pregnancy data are limited. Uncontrolled high phenylalanine can harm fetal development; treatment decisions require specialist assessment and close monitoring.
Breastfeeding
It is unknown whether pegvaliase passes into breast milk; weigh potential benefits and risks with a healthcare professional.
Interactions
- May lower blood phenylalanine enough to require changes to dietary phenylalanine intake.
- No well-established major medicine interactions are known.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.